Development of the molecular target therapy for the inflammatory bowel disease
| Project/Area Number |
16H05169
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Sato Kazuki
Kanemaru Yumi (Yamashita Yumi)
Abe Fumie
Nakamura Yuho
Murata Rikito
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2018: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2016: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | 免疫学 / 免疫受容体 / 制御性T細胞 / 炎症 / 免疫系受容体 / 炎症性腸炎 / 炎症性腸疾患 |
|---|
| Outline of Final Research Achievements |
The inflammatory bowel disease is an intractable disease with chronic inflammation of the intestinal mucosa. Treg cells play an important role to suppress immune response-induced inflammation. In this study, we show that DNAM-1, an immunoreceptor expressed on Tregs, induces instability in the expression of Foxp3, a master regulator of Tregs, in the inflammatory environment and limits the immunosuppressive capacity of Tregs. Thus, DNAM-1 may be a good therapeutic target for the control of inflammatory bowel disease associated with Treg dysfunction.
|
| Academic Significance and Societal Importance of the Research Achievements |
クローン病や潰瘍性大腸炎に代表される炎症性腸疾患は、腸粘膜の慢性炎症を主徴とする原因不明の難治性疾患である。わが国の患者数は年々増加おり、H25年には20万人を超えた。しかし、根治的治療法が未だ確立されていないことより、早急な治療法の開発が望まれている。制御性T細胞 (Treg) は、炎症性腸疾患の病態制御に重要な役割を担っている。本研究において、DNAM-1欠損はAKT-mTORC1経路が抑制し、安定したFoxp3発現を促して、Tregの抑制機能を亢進することが明らかになった。このことは、Tregの機能不全を伴う炎症性疾患の制御にDNAM-1が良い治療標的となりうることを示唆している。
|
Report
(4 results)
Research Products
(52 results)
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Soluble DNAM-1, as a predictive biomarker for acute graft-versus-host disease2016
Author(s)
Kanaya M, Shibuya K, Hirochika R, Kanemoto M, Ohashi K, Okada M, Wagatsuma Y, Cho Y, Kojima H, Teshima T, Imamura M, Sakamaki H, Shibuya A.
-
Journal Title
PLoS ONE
Volume: 11
Issue: 6
Pages: e0154173-e0154173
DOI
NAID
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Increased soluble CD155 in the serum of cancer patients2016
Author(s)
Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, Sato T, Yoshikawa H, Hara H, Shibuya A, Shibuya K.
-
Journal Title
PLoS One
Volume: 11(4)
Issue: 4
Pages: 1-12
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Apoptotic epithelial cells control the abundance of regulatory T cells at barrier surfaces.2016
Author(s)
Nakahashi-Oda C, Udayanga K. G. S, Nakamura Y, Nakazawa Y, Totsuka N, Miki H, Iino S, Tahara-Hanaoka S, Honda S, Shibuya K, Shibuya A.
Organizer
International Congress of Immunology 2016
Place of Presentation
Melbourne (Australia)
Year and Date
2016-08-22
Related Report
Int'l Joint Research
-
-
-
-
-
-
